Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune

This page shows the latest Adaptimmune news and features for those working in and with pharma, biotech and healthcare.

GSK and Bayer strike new biotech cancer deals

GSK and Bayer strike new biotech cancer deals

GSK and Bayer strike new biotech cancer deals. Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines. ... GSK has agreed a $350m deal with US-based Adaptimmune to develop T-cell receptors to target a range of

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific peptide-enhanced affinity receptor T cell immunotherapies in solid and haematological cancers.

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2).

  • Pharma deals during June 2014 Pharma deals during June 2014

    Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. ... Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    Adaptimmune appoints Lawrence Alleva to its board. The former PwC partner will also chair its boardaudit committee. ... Adaptimmune has appointed former PwC partner Lawrence (Larry) Alleva to its board of directors as an independent, non-executive

  • Adaptimmune appoints former GSK executives Adaptimmune appoints former GSK executives

    Dr Amado said: “ I am pleased to be joining Adaptimmune at this exciting time. ... Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics